Printer Friendly

EMBREX STOCK OFFERING NETS $16.8 MILLION

 EMBREX STOCK OFFERING NETS $16.8 MILLION
 RESEARCH TRIANGLE PARK, N.C., Dec. 23 /PRNewswire/ -- Embrex Inc.


(NASDAQ: EMBX, EMBXW) today announced that the final net proceeds from the company's initial public offering of common stock and redeemable warrants were approximately $16.8 million. The amount includes the recent sale of an additional 70,000 shares of common stock to the underwriter, Josephthal Lyon & Ross Incorporated (New York), to cover over-allotments from the public offering.
 On Nov. 15, Embrex closed its initial public offering with the sale of 2.2 million shares of common stock at $8.50 per share and 2.530 million redeemable warrants at $0.10 per warrant. This included the sale to the underwriter of an additional 330,000 redeemable warrants to cover over-allotments.
 The most recent sale of common stock to Josephthal brings the number of shares of common stock outstanding to 3,777,054. The number of redeemable warrants outstanding remains 2,557,000.
 Embrex Inc. develops and has recently begun marketing bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry.
 -0- 12/23/91
 /CONTACT: John A. Hagan of Embrex, 919-941-5185; or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/
 (EMBX) CO: Embrex Inc. ST: North Carolina IN: MTC SU: OFR


GK -- NY007 -- 4707 12/23/91 08:28 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1991
Words:222
Previous Article:P. LEINER NUTRITIONAL PRODUCTS CORP. ANNOUNCES AGREEMENT UNDER WHICH IT WILL GO PRIVATE
Next Article:GAMMA INTERNATIONAL GRANTED EXCEPTION FROM NASD REQUIREMENT
Topics:


Related Articles
EMBREX REGISTRATION STATEMENT DECLARED EFFECTIVE
EMBREX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
EMBREX REPORTS FOURTH QUARTER AND YEAR-END RESULTS
EMBREX REPORTS FIRST-QUARTER RESULTS
Embrex Europe Announces Key Appointments, $2 Million Bank Credit Line To Support Rapid International Expansion
Embrex Achieves Record Revenues, Net Income in Third Quarter
Embrex Reports First-Time Annual Profit, Record Revenues For 1996
Correction To Embrex April 14 Release Company's Patent License Is Exclusive(Correction Notice)
Embrex, Tyson Agree On Long-Term Inovoject System Contract

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters